Monoclonal antibodies for treatment of cancer
The present invention provides antibodies useful as therapeutics for treating and/or preventing diseases associated with cells expressing GT468, including tumor-related diseases such as breast cancer, lung cancer, gastric cancer, ovarian cancer, hepatocellular cancer, colon cancer, pancreatic cancer, esophageal cancer, head & neck cancer, kidney cancer, in particular renal cell carcinoma, prostate cancer, liver cancer, melanoma, sarcoma, myeloma, neuroblastoma, placental choriocarcinoma, cervical cancer, and thyroid cancer, and the metastatic forms thereof. In one embodiment, the tumor disease is metastatic cancer in the lung.
1. An isolated antibody that binds human GT468 selected from the group consisting of:
(i) an antibody comprising six complementarity determining regions (CDRs), wherein said antibody is produced by a hybridoma deposited under the accession number DSM ACC3039 (4A5 1E11 1B7), DSM ACC3037 (7H12 2E6 2C4), DSM ACC3036 (11 D7 1G10 2B4), DSM ACC3038 (18-2A-1), DSM ACC3040 (63-1A-2), or DSM ACC3042 (3E5 2G4),
(ii) a chimerized or humanized antibody comprising the six CDRs of the antibody under (i), and
(iii) an antibody comprising the six complementarity determining regions (CDRs) of the antibody under (i).
2. A hybridoma deposited under the accession number DSM ACC3039 (4A5 1E11 1B7), DSM ACC3037 (7H12 2E6 2C4), DSM ACC3036 (11 D7 1G10 2B4), DSM ACC3038 (18-2A-1), DSM ACC3040 (63-1A-2), or DSM ACC3042 (3E5 2G4).
3. A conjugate comprising an isolated antibody of claim 1 coupled to a therapeutic agent.
4. The conjugate of claim 3 wherein the therapeutic agent is a toxin, a radioisotope, a drug or a cytotoxic agent.
5. A pharmaceutical composition comprising an isolated antibody of claim 1 and/or a conjugate of claim 3 or 4 , and a pharmaceutically acceptable carrier.
6. An isolated host cell capable of expressing a chimerized or a humanized antibody that binds human GT468 comprising the six complementarity determining regions (CDRs) of an antibody produced by the hybridoma of claim 2 .